We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure [email protected]
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Drug discovery and development pipelines are timely consuming and expensive, depending on numerous factors. Artificial intelligence (AI) tools are increasingly being applied in drug discovery for Alzheimer’s disease (AD). In the “big data” era, AI offers cutting-edge applications of informatics and computational tools for re-defining disease biology, discovering new therapeutics, and identifying novel targets with the least errors. The application of AI has the potential to enhance the pipeline across all stages of drug discovery and reduce failure rates in drug development for AD. In this chapter, we introduce AI techniques accessible for accelerating drug discovery. We summarize representation learning, machine learning, and deep learning toolboxes, available for drug discovery. We illustrate the application of AI for target identification, evaluation of pharmacokinetic properties (i.e., brain penetration), safety, and identification of biomarkers in clinical trials. We discuss current challenges and future directions of AI-based solutions for drug discovery. Rapidly developing, powerful and innovative AI technologies can expedite drug discovery and development for AD.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.